Literature DB >> 3710767

Release of tumor necrosis factor (TNF) into mouse peritoneal fluids by OK-432, a streptococcal preparation.

A Yamamoto, M Nagamuta, H Usami, Y Sugawara, N Watanabe, Y Niitsu, I Urushizaki.   

Abstract

A cytotoxic factor was induced in peritoneal fluid by injection of OK-432 in mice which had been primed with OK-432. Two-step stimulation (priming and eliciting) was always necessary to induce the cytotoxic factor. OK-432-primed mice did not produce soluble cytotoxic factor spontaneously and no cytotoxic activity was detected in the mice treated by a single injection of OK-432 as an eliciting agent. This observation was also confirmed by in vitro experiments. Only when activated macrophages were incubated with OK-432 (or with lipopolysaccharide) was cytotoxin released into medium supernatant. High doses of OK-432 were required to prime mice for the production of cytotoxic factor, whereas a small amount was enough to elicit. The peritoneal cytotoxic factor obtained by OK-432 injection appears to be identical to tumor necrosis factor in the serum for the following reasons: The two factors are similar in mode of cytotoxic action. Both are produced from macrophages. They are similar in physicochemical characteristics. The cytotoxicity of the peritoneal cytotoxic factor was totally abolished by anti-TNF serum.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3710767     DOI: 10.1016/0162-3109(86)90027-5

Source DB:  PubMed          Journal:  Immunopharmacology        ISSN: 0162-3109


  18 in total

1.  Mechanism of immunotherapeutic activity of OK-432 in the treatment of peritoneal carcinomatosis.

Authors:  H Fukui; C W Reynolds; B Lenz; M Schneider; J E Talmadge
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

2.  Autoimmune kidney disease in MRL/Mp-lpr/lpr mice inhibited by OK-432, a streptococcal preparation.

Authors:  M Mihara; Y Ohsugi
Journal:  Clin Exp Immunol       Date:  1989-10       Impact factor: 4.330

Review 3.  Evaluation of TNF as antiviral, antibacterial and antiparasitic agent.

Authors:  G A Rook; J Taverne; J H Playfair
Journal:  Biotherapy       Date:  1991

4.  The role of gamma-interferon, vitamin D3 metabolites and tumour necrosis factor in the pathogenesis of tuberculosis.

Authors:  G A Rook; J Taverne; C Leveton; J Steele
Journal:  Immunology       Date:  1987-10       Impact factor: 7.397

5.  Proliferative responses of peripheral blood mononuclear cells from psoriatic patients to T lymphocyte-stimulating cytokines (IL-2, IL-3, IL-4, and granulocyte-macrophage colony-stimulating factor) and OK-432.

Authors:  S Aiba; H Tagami
Journal:  Arch Dermatol Res       Date:  1989       Impact factor: 3.017

6.  Induction of tumor necrosis factor alpha by spherules of Coccidioides immitis.

Authors:  D C Slagle; R A Cox; U Kuruganti
Journal:  Infect Immun       Date:  1989-07       Impact factor: 3.441

7.  The possible use of spleen cells for the adoptive immunotherapy of cancer patients.

Authors:  M Katano; H Yamamoto; E Kubota; M Nakamura; T Matsuo; F Nagumo; T Hisatsugu; T Katsuki; J Tadano
Journal:  Surg Today       Date:  1993       Impact factor: 2.549

8.  Recruitment of T lymphocytes and induction of tumor necrosis factor in thyroid cancer by a local immunotherapy.

Authors:  T Misaki; Y Watanabe; Y Iida; A Hidaka; K Kasagi; H Fukushima; J Konishi
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

9.  Intraarterial combined immunochemotherapy for unresectable hepatocellular carcinoma: preliminary results.

Authors:  M Oka; S Hazama; S Yoshino; K Shimoda; M Suzuki; R Shimizu; K Yano; M Nishida; T Suzuki
Journal:  Cancer Immunol Immunother       Date:  1994-03       Impact factor: 6.968

10.  Induction of tumor growth inhibitory factor (TGIF) in human mononuclear cells by OK-432, a streptococcal preparation.

Authors:  M Katano; H Yamamoto; T Mizoguchi; T Hisatsugu
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.